Cognoa provides Canvas Dx, an FDA‑authorized AI‑driven platform that lets clinicians diagnose autism in children aged 1.5–6 years within days using remote, video‑based assessments. The solution captures behavioral data, applies proprietary machine‑learning models to generate objective diagnostic recommendations, and integrates with clinical workflows and insurance billing to reduce wait times, lower costs, and improve equity in early intervention.
Funding
$73.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Children with autism and other developmental conditions are often diagnosed after several years, delaying access to effective interventions. Geographic distance, limited specialty resources, and systemic biases further prevent timely and equitable diagnosis, especially for underserved populations.
Solution
Cognoa offers Canvas Dx, an FDA‑authorized, AI‑driven diagnostic platform that enables clinicians to evaluate children aged 1.5–6 years for autism within days rather than months. The solution uses a remote, digital assessment workflow that captures behavioral data through guided video interactions, which are then analyzed by proprietary machine‑learning models to generate an objective diagnostic recommendation. By delivering rapid, data‑based results, Canvas Dx reduces diagnostic wait times, lowers associated healthcare costs, and mitigates bias in decision‑making. The platform integrates with existing clinical workflows and is reimbursable through insurers such as Highmark and Medicaid programs, expanding access to early intervention for diverse families.
Target Audience
Primary customers are pediatricians, developmental‑behavioral specialists, and early‑intervention programs seeking a fast, reliable autism diagnostic tool, as well as families and caregivers of children with developmental concerns.
Features
- FDA‑cleared AI diagnostic algorithm for autism spectrum disorder in children 1.5–6 years old
- Remote, video‑based assessment that can be completed at home or in community settings
- Automated data capture and analysis delivering results within days
- Objective, bias‑reducing scoring system based on validated behavioral markers
- Integration with electronic health records and billing systems for seamless clinical use
- Insurance reimbursement support, including Medicaid and private payer coverage